New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Study backs pTeroPure's weight management benefits

Study backs pTeroPure's weight management benefits
Recent study published in the Journal of Agricultural and Food Chemistry has demonstrated the weight loss effects of pterostilbene in rats fed an obesogenic diet. 

A recent study led by Saioa Gomez-Zorita published in the Journal of Agricultural and Food Chemistry has demonstrated the weight loss effects of pterostilbene in rats fed an obesogenic diet. The study confirms the results of a 2012 human clinical trial on the effect of pterostilbene on weight loss conducted by ChromaDex (CDXC), an innovative natural products company that manufactures a proprietary pterostilbene ingredient, pTeroPure®.

Researchers involved with the newly published study, conducted by The University of Basque Country's nutrition and obesity group in collaboration with the United States Department of Agriculture, observed in animal models that the administration of pterostilbene reduces the buildup of body fat, which may help support healthy blood glucose levels.  

In 2012, Irvine, Calif.-based ChromaDex, which provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, conducted human clinical trials that also demonstrated the effects of pterostilbene on weight loss.

USDA research chemist Agnes M. Rimando, a named collaborator on the Gomez-Zorita study, is one of the inventors of the USDA pterostilbene patents licensed by ChromaDex.

The new data from the Gomez-Zorita animal study is fully consistent with results achieved by ChromaDex in the Phase 2/3 clinical study of its pTeroPure pterostilbene. The study demonstrated that participants taking pTeroPure at 100 milligram per day lost 3.04 pounds at confidence interval of 94.45 percent (p=0.055). Although statistical significance is based at a 95 percent confidence interval, the data trended toward significance. The study also showed statistically significant results for pterostilbene's ability to support normal blood pressure without any serious adverse side effects.

ChromaDex's patented pterostilbene—branded as pTeroPure—was named the 2010 North American Most Promising Ingredient of the Year by the independent research company Frost & Sullivan. ChromaDex launched pTeroPure in 2010 and today, more than 40 consumer products containing pTeroPure are available in the marketplace.

In 2010, ChromaDex announced an exclusive worldwide license for all patent rights of pterostilbene with the University of Mississippi and the USDA Agricultural Research Service. In April 2014, a collaboration formed by the University of Mississippi's Division of Technology Management, the USDA Agricultural Research Service's Natural Products Utilization Research Unit and ChromaDex won a Federal Laboratory Consortium 2014 Excellence in Technology Transfer Award for their work developing pterostilbene.

Commenting on the recent study, Frank Jaksch, cofounder and CEO of ChromaDex, stated: "This recently published study further confirms there is a connection between pterostilbene and weight loss. With regard to the pterostilbene human study that we conducted in 2012, we were surprised with the significant trend in weight loss, considering it was only an eight-week study. Given the challenges of finding effective, science-backed weight loss ingredients, our pTeroPure pterostilbene provides the market with an excellent solution."       


Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.